Compare CATY & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CATY | LQDA |
|---|---|---|
| Founded | 1962 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | N/A | 2018 |
| Metric | CATY | LQDA |
|---|---|---|
| Price | $54.22 | $42.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $52.75 | $38.60 |
| AVG Volume (30 Days) | 382.8K | ★ 2.3M |
| Earning Date | 01-22-2026 | 03-18-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | ★ 14.94 | N/A |
| EPS | ★ 4.54 | N/A |
| Revenue | ★ $745,261,000.00 | $69,216,000.00 |
| Revenue This Year | $20.37 | $993.31 |
| Revenue Next Year | $5.41 | $219.14 |
| P/E Ratio | $11.92 | ★ N/A |
| Revenue Growth | 7.66 | ★ 343.41 |
| 52 Week Low | $36.06 | $11.26 |
| 52 Week High | $54.99 | $46.67 |
| Indicator | CATY | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 66.92 | 56.32 |
| Support Level | $49.78 | $41.34 |
| Resistance Level | $54.99 | $46.67 |
| Average True Range (ATR) | 1.56 | 2.50 |
| MACD | 0.33 | -0.19 |
| Stochastic Oscillator | 87.21 | 43.80 |
Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities and advisory services.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.